Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Therapy-induced senescence reprograms non-M3 AML into a drug-exploitable APL-like state

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMartin SchönleinPRPaulina Richter‐PechańskaJIJana Ihlow

Discussion

Loading...

Member takes

Overview

Cellular senescence reprograms acute myeloid leukemias into an APL-like state, suggesting new therapies may improve outcomes.

Key Points

  • To explore how therapy-induced senescence affects non-M3 acute myeloid leukemias and induces an APL-like state.
  • Characterization of therapy-induced senescence through ex vivo assays and gene expression profiling.
  • Analysis of plasticity-related vulnerabilities in primary AML blasts using various chemotherapeutic agents.
  • Validation of findings in patient-derived xenograft models and transcriptomic analysis of AML cohorts.
  • Therapy-induced senescence reprogrammed non-M3 AML blasts towards an acute promyelocytic leukemia-like phenotype.
  • The ancestral transcriptomes provided insights into treatment sensitivities and outcomes.
  • TIS capacity predicted disease-free and overall survival in patients, emphasizing its clinical relevance.

Cite This Study

Schönlein et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4b1https://doi.org/10.1182/blood-2025-3244
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Therapy induced senescence promotes immunogenicity in acute myeloid Leukemia through reduced EZH2 activity2026
  2. 2Abstract 6475: Myeloma cells with therapy-induced senescence-like phenotype have increased resistance to killing by T cell directed therapies2026
  3. 3Therapy-Induced Cellular Senescence in Non-Hodgkin Lymphomas, with Emphasis on Aggressive B-Cell Subtypes: Molecular Mechanisms and Emerging Drug Targets2026
  4. 4Abstract LB150: Senescence as an immune tolerance breaker: Inhibitors of mitotic kinases TTK (Mps1) and AURKA induce pro-immunogenic senescence that primes the tumor microenvironment for immunotherapy via cGAS-STING signaling2026
  5. 5Abstract 6467: Myeloma cells with therapy-induced senescence-like phenotype are associated with resistance to CAR-T therapy2026